Role of donor activating KIR-HLA ligand-mediated NK Cell education status in control of malignancy in hematopoietic cell transplant recipients

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 5, 2015, Pages 829-839

  Nowak, Jacek ^a   Kościńska, Katarzyna ^b   Mika Witkowska, Renata ^a   Rogatko Koroś, Marta ^a   Mizia, Sylwia ^b   Jaskuła, Emilia ^c   Polak, Małgorzata ^b   Mordak Domagała, Monika ^b   Lange, Janusz ^b   Gronkowska, Anna ^d   Jedrzejczak, Wiesław Wiktor ^d   Kyrcz Krzemień, Sławomira ^e   Markiewicz, Mirosław ^e   Dzierzak Mietła, Monika ^e   Tomaszewska, Agnieszka ^a   Nasiłowska Adamska, Barbara ^a   Szczepiński, Andrzej ^a   Hałaburda, Kazimierz ^a   Hellmann, Andrzej ^f   Czyz, Anna ^g   Gil, Lidia ^g   Komarnicki, Mieczysław ^g   Wachowiak, Jacek ^g   Barańska, Małgorzata ^g   Kowalczyk, Jerzy ^h   Drabko, Katarzyna ^h   Goździk, Jolanta ⁱ   Wysoczańska, Barbara ^c   Bogunia Kubik, Katarzyna ^c   Graczyk Pol, Elzbieta ^a   Witkowska, Agnieszka ^a   Marosz Rudnicka, Anna ^a   Nestorowicz, Klaudia ^a   Dziopa, Joanna ^a   Szlendak, Urszula ^a   Warzocha, Krzysztof ^a   Lange, Andrzej ^b,c   more..

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^b Lower Silesian Center for Cellular Transplantation with National Bone Marrow Donor Registry   (Poland)

^c INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

^f MEDICAL UNIVERSITY OF GDANSK   (Poland)

^g POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^h MEDICAL UNIVERSITY OF LUBLIN   (Poland)

ⁱ UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

Author keywords

Activating killer cell immunoglobulin like receptors; Bone marrow donor selection; Hematopoietic stem cell transplantation; Malignant diseases; Missing ligand; Natural killer cell education

Indexed keywords

HLA ANTIGEN; HLA ANTIGEN CLASS 1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LIGAND;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CONTROL; CANCER PATIENT; CHILD; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; ORGAN DONOR; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; ALLOGRAFT; CLINICAL TRIAL; FEMALE; GENETICS; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; INFANT; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PRESCHOOL CHILD; UNRELATED DONORS;

ADOLESCENT; ADULT; ALLOGRAFTS; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS TUMOR EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; RECEPTORS, KIR; UNRELATED DONORS;

EID: 84928209254     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.01.018     Document Type: Article

References (51)

1. Sun J.C., Beilke J.N., Bezman N.A., Lanier L.L. Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection. JExp Med 2011, 208:357-368.
2. Re F., Staudacher C., Zamai L., et al. Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors. Cancer 2006, 107:640-648.
3. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
4. Ruggeri L., Mancusi A., Capanni M., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110:433-440.
5. Willemze R., Rodrigues C.A., Labopin M., et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009, 23:492-500.
6. Pende D., Marcenaro S., Falco M., et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009, 113:3119-3129.
7. Giebel S., Locatelli F., Lamparelli T., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003, 102:814-819.
8. Long E.O., Rajagopalan S. HLA class I recognition by killer cell Ig-like receptors. Semin Immunol 2000, 12:101-108.
9. Long E.O., Barber D.F., Burshtyn D.N., et al. Inhibition of natural killer cell activation signals by killer cell immunoglobulin-like receptors (CD158). Immunol Rev 2001, 181:223-233.
10. Kim S., Poursine-Laurent J., Truscott S.M., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436:709-713.
11. Parham P. The genetic and evolutionary balances in human NK cell receptor diversity. Semin Immunol 2008, 20:311-316.
12. Graef T., Moesta A.K., Norman P.J., et al. KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. JExp Med 2009, 206:2557-2572.
13. David G., Djaoud Z., Willem C., et al. Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 SPECIFICITY of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation. JImmunol 2013, 191:4778-4788.
14. Chewning J.H., Gudme C.N., Hsu K.C., et al. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group invitro. JImmunol 2007, 179:854-868.
15. Venstrom J.M., Pittari G., Gooley T.A., et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. NEngl J Med 2012, 367:805-816.
16. Karre K., Ljunggren H.G., Piontek G., Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986, 319:675-678.
17. Lanier L.L. Missing self, NK cells, and the White Album. JImmunol 2005, 174:6565.
18. Ljunggren H.G., Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990, 11:237-244.
19. Fernandez N.C., Treiner E., Vance R.E., et al. Asubset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005, 105:4416-4423.
20. Thomas L.M., Peterson M.E., Long E.O. Cutting edge: NK cell licensing modulates adhesion to target cells. JImmunol 2013, 191:3981-3985.
21. Jonsson A.H., Yokoyama W.M. Assessing licensing of NK cells. Methods Mol Biol 2010, 612:39-49.
22. Jonsson A.H., Yokoyama W.M. Natural killer cell tolerance licensing and other mechanisms. Adv Immunol 2009, 101:27-79.
23. Fauriat C., Ivarsson M.A., Ljunggren H.G., et al. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 2010, 115:1166-1174.
24. Passweg J.R., Baldomero H., Gratwohl A., et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012, 47:906-923.
25. Nowak J., Mika-Witkowska R., Graczyk-Pol E. Genetic methods of HLA typing, in Molecular Aspects of Hematologic Malignancies 2012, Vol. 21:225-239. Springer-Verlag, Berlin Heidelberg.
26. Joncker N.T., Shifrin N., Delebecque F., Raulet D.H. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. JExp Med 2010, 207:2065-2072.
27. Robinson J., Halliwell J.A., McWilliam H., et al. The IMGT/HLA database. Nucleic Acids Res 2013, 41(Database issue):D1222-D1227.
28. Dorak M.T. Major histocompatibility complex 2014, Vol. 2014. Liverpool Hope University, Liverpool, UK, Available at:. http://www.dorak.info.hla.
29. Foley B.A., De Santis D., Van Beelen E., et al. The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantations. Blood 2008, 112:435-443.
30. Nowak J., Kościńska K., Mika-Witkowska R., et al. Donor NK cell licensing in control of malignancy in hematopoietic stem cell transplant recipients. Am J Hematol 2014, 89:E176-E183.
31. Nowak J., Mika-Witkowska R., Rogatko-Koros M., et al. Repertoire ofMHC-KIR ligands in the Polish population. Tissue Antigens 2010, 75:526.
32. Nowak J., Mika-Witkowska R., Polak M., et al. Allele and extended haplotype polymorphism of HLA-A, -C, -B, -DRB1 and -DQB1 loci in Polish population and genetic affinities to other populations. Tissue Antigens 2008, 71:193-205.
33. Moesta A.K., Norman P.J., Yawata M., et al. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. JImmunol 2008, 180:3969-3979.
34. Boyington J.C., Brooks A.G., Sun P.D. Structure of killer cell immunoglobulin-like receptors and their recognition of the class I MHC molecules. Immunol Rev 2001, 181:66-78.
35. Yawata M., Yawata N., Draghi M., et al. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. JExp Med 2006, 203:633-645.
36. Kröger N., Binder T., Zabelina T., et al. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after invivo T-cell depleted unrelated stem cell transplantation. Transplantation 2006, 82:1024-1030.
37. Schellekens J., Rozemuller E.H., Petersen E.J., et al. Activating KIRs exert a crucial role on relapse and overall survival after HLA-identical sibling transplantation. Mol Immunol 2008, 45:2255-2261.
38. Smith H.R., Chuang H.H., Wang L.L., et al. Nonstochastic coexpression of activation receptors on murine natural killer cells. JExp Med 2000, 191:1341-1354.
39. Li H., Pascal V., Martin M.P., et al. Genetic control of variegated KIR gene expression: polymorphisms of the bi-directional KIR3DL1 promoter are associated with distinct frequencies of gene expression. PLoS Genet 2008, 4:e1000254.
40. Kim S., Sunwoo J.B., Yang L., et al. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci U S A 2008, 105:3053-3058.
41. Middleton D., Gonzalez A., Gilmore P.M. Studies on the expression of the deleted KIR2DS4*003 gene product and distribution of KIR2DS4 deleted and nondeleted versions in different populations. Hum Immunol 2007, 68:128-134.
42. Moretta A., Bottino C., Vitale M., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001, 19:197-223.
43. Romagné F., Vivier E. Natural killer cell-based therapies. F1000 Med Rep 2011, 3:9.
44. Huang B., Sikorski R., Sampath P., Thorne S.H. Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer. JImmunother 2011, 34:289-296.
45. Ljunggren H.G., Kärre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990, 11:237-244.
46. Vyas Y.M., Mehta K.M., Morgan M., et al. Spatial organization of signal transduction molecules in the NK cell immune synapses during MHC class I-regulated noncytolytic and cytolytic interactions. JImmunol 2001, 167:4358-4367.
47. Osman M.S., Burshtyn D.N., Kane K.P. Activating Ly-49 receptors regulate LFA-1-mediated adhesion by NK cells. JImmunol 2007, 178:1261-1267.
48. Bryceson Y.T., Ljunggren H.G., Long E.O. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood 2009, 114:2657-2666.
49. Orr M.T., Murphy W.J., Lanier L.L. 'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection. Nat Immunol 2010, 11:321-327.
50. Kwant-Mitchell A., Pek E.A., Rosenthal K.L., Ashkar A.A. Development of functional human NK cells in an immunodeficient mouse model with the ability to provide protection against tumor challenge. PLoS One 2009, 4:e8379.
51. Luevano M., Madrigal A., Saudemont A. Generation of natural killer cells from hematopoietic stem cells invitro for immunotherapy. Cell Mol Immunol 2012, 9:310-320.